DS
KPRX icon

DRW Securities’s Kiora Pharmaceuticals KPRX Stock Holding History

DRW Securities’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-110,282
Closed -$217K – 1542
2025
Q4 		$217K Buy
110,282
+73,417
+199% +$167K 0.01% 909
2025
Q3 		$102K Buy
+36,865
New +$101K ﹤0.01% 1180

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DRW Securities's KPRX Position: Q1 2026 in Review

DRW Securities sold out of Kiora Pharmaceuticals (KPRX) in Q1 2026, closing a stake of 110,282 shares — an estimated $217K sold.

DRW Securities first reported a position in KPRX in Q3 2025 and held it in 2 quarters. The position peaked at $217K in Q4 2025. 18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.

  • DRW Securities reported no remaining Kiora Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 110,282 Kiora Pharmaceuticals shares in Q1 2026, an estimated $217K.
  • DRW Securities first reported a position in Kiora Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • DRW Securities's Kiora Pharmaceuticals position peaked at $217K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.